Ftse Mib
33.311,37
1,23%
DAX
18.131,97
0,32%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
64.733,98
-2,64%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Shuttle Pharmaceuticals Holdings Inc (SHPH) Shuttle Pharmaceuticals Holdings Inc (SHPH) Notizie

SHPH

Shuttle Pharmaceuticals (SHPH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SHPH
DataOraFonteTitoloSimboloCompagnia
18/06/202415:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
18/06/202415:00GlobeNewswire Inc.Shuttle Pharma Appoints Timothy Lorber as Chief Financial OfficerNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
10/06/202412:12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/05/202422:15GlobeNewswire Inc.Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/05/202415:00GlobeNewswire Inc.Shuttle Pharma Provides First Quarter 2024 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/05/202423:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/04/202422:15GlobeNewswire Inc.Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
22/03/202414:00PR Newswire (US)Shuttle Pharma Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
09/03/202400:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/02/202414:00PR Newswire (US)Shuttle Pharma Announces Its Intent to Pursue a Rights OfferingNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
23/01/202422:30PR Newswire (US)Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
08/01/202415:00PR Newswire (US)Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/12/202315:00PR Newswire (US)Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
14/11/202315:00PR Newswire (US)Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
31/10/202314:00PR Newswire (US)Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License AgreementNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202322:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
20/10/202322:10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
10/10/202315:00PR Newswire (US)Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
25/09/202315:00PR Newswire (US)Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
13/09/202315:00PR Newswire (US)Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health FairNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
11/09/202315:00PR Newswire (US)Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor PlatformNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
29/08/202315:00PR Newswire (US)Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer TherapeuticsNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
24/08/202320:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
15/08/202315:00PR Newswire (US)Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
03/08/202315:00PR Newswire (US)Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical TrialNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
16/06/202312:31Edgar (US Regulatory)Information Statement - All Other (definitive) (def 14c)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
05/06/202322:29Edgar (US Regulatory)Proxy Statement - Other Information (preliminary) (pre 14c)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
30/05/202323:31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
26/05/202315:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
26/05/202315:00PR Newswire (US)Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate UpdateNASDAQ:SHPHShuttle Pharmaceuticals Holdings Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SHPH

La tua Cronologia

BIT
UB3YG6
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network